Pharmaceuticals company Supriya Lifescience announced Q3FY25 results In the third quarter of FY25, Supriya Lifescience witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs 185.65 crore compared to Rs 140.07 crore in Q3FY24. Gross Profit for Q3FY25 stood at Rs 123.87 crore, with a growth of 45% compared to Rs 85.45 crore in Q3FY24. EBITDA for Q3FY25 stood at Rs 65.95 crore, with an EBITDA Margin of 35.50%, as opposed to an EBITDA of Rs 41.49 crore in Q3FY24 with an EBITDA margin of 29.60%. This marks an improvement of 591 bps YoY. The Profit After Tax (PAT) increased by 57% for Q3FY25 to Rs 46.78 crore, compared to Rs 29.78 crore in Q3FY24. The PAT Margin stood at 25.2% in Q3FY25, compared to 21.30% in Q3FY24. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience, commenting on the results, said, “Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% YoY revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth." Result PDF
Conference Call with Supriya Lifescience Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.